Factor IX replacement to cover total knee replacement surgery in haemophilia B: A single-centre experience, 2000-2010

Haemophilia

Volumn 18, Issue 1, 2012, Pages 46-49

  Uprichard, J ^a   Adamidou, D ^a   Goddard, N J ^a   Mann, H A ^a   Yee, T T ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Continuous infusion; FIX; Haemarthropathy; Haemophilia B; Knee replacement; Surgery

Indexed keywords

BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9 CONCENTRATE; HAEMONINE; RECOMBINANT BLOOD CLOTTING FACTOR 9; REPLENINE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD TRANSFUSION; CLINICAL ARTICLE; CONTINUOUS INFUSION; DISEASE SEVERITY; ELBOW INJURY; FEMALE; HEMOPHILIA A; HEMOPHILIA B; HUMAN; LENGTH OF STAY; MALE; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; PROFESSIONAL STANDARD; TOTAL KNEE REPLACEMENT;

ADULT; AGED; ARTHROPLASTY, REPLACEMENT, KNEE; FACTOR IX; HEMARTHROSIS; HEMOPHILIA B; HEMOSTASIS, SURGICAL; HUMANS; LENGTH OF STAY; METABOLIC CLEARANCE RATE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; RETROSPECTIVE STUDIES;

EID: 84355163092     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2011.02552.x     Document Type: Article

References (17)

1. Tagariello G, Iorio A, Santagostino E et al. Comparison of the rates of joint arthroplasty in patients with severe factor VIII and IX deficiency: an index of different clinical severity of the 2 coagulation disorders. Blood 2009; 114: 779-84.
2. Goddard NJ, Mann HA, Lee CA. Total knee replacement in patients with end-stage haemophilic arthropathy: 25-year results. J Bone Joint Surg Br 2010; 92: 1085-9.
3. Brinkhous KM. Hemophilia. Bull N Y Acad Med 1954;30, 325-42.
4. Hermens WTH. Dose calculation of human factor VIII and factor IX concentrates for infusion therapy. In: Brinkhous KM, Hemker HC eds. Handbook of Hemophilia. New York: American Elsevier Publishing, 1975: 569-89.
5. Hay CR, Doughty HI, Savidge GF. Continuous infusion of factor VIII for surgery and major bleeding. Blood Coagul Fibrinolysis 1996; 7(Suppl. 1): S15-9.
6. Morfini M. Secondary prophylaxis with factor IX concentrates: continuous infusion. Blood Transfus 2008; 6(Suppl. 2): s21-5.
7. Noe DA, Bell WR, Ness PM, Levin J. Plasma clearance rates of coagulation factors VIII and IX in factor-deficient individuals. Blood 1986; 67: 969-72.
8. Chowdary P, Dasani H, Jones JA et al. Recombinant factor IX (BeneFix) by adjusted continuous infusion: a study of stability, sterility and clinical experience. Haemophilia 2001; 7: 140-5.
9. Douvas MG, Monahan PE. Life-threatening thrombosis complicating the management of hepatic hemorrhage: anticoagulant treatment in a newborn with hemophilia B. J Pediatr Hematol Oncol 2004; 26: 258-63.
10. Machin SJ, Miller BE. Thrombosis and factor-IX concentrates. Lancet 1978; 1: 1367.
11. Yaish H, Rodgers GM. A haemophilia B patient with severe burn injury: increased requirement for factor IX replacement therapy associated with venous thromboembolism. Haemophilia 2008; 14: 607-9.
12. Nilsson IM, Berntorp E, Lofqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992; 232: 25-32.
13. Darby SC, Kan SW, Spooner RJ et al. Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV. Blood 2007; 110: 815-25.
14. Larsson SA. Life expectancy of Swedish haemophiliacs, 1831-1980. Br J Haematol 1985; 59: 593-602.
15. Mannucci PM, Schutgens RE, Santagostino E, Mauser-Bunschoten EP. How I treat age-related morbidities in elderly persons with hemophilia. Blood 2009; 114: 5256-63.
16. Morfini M. Pharmacokinetics of factor VIII and factor IX. Haemophilia 2003;9(Suppl. 1), 94-9. discussion 100.
17. EMEA. Note for the Guidance on the Clinical Investigation of Human Plasma Derived Factor VIII and IX Products. 2000, CPMP/BPWG/198/95.